BENZOPYRAN DERIVATIVES

Abstract: A benzopyran derivative represented by formula wherein: R₁ and R₂ each represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted cyclic alkyl group, a mono- or di-lower alkylamino group, a substituted or un­ substituted cyclic amino group, a substituted or unsubstitu­ ted aryl group, or a substituted or unsubstituted aralkyl group; Y₁ and Y₂ each represents a hydrogen atom, a lower alkyl group, a halogen atom or a trihalomethyl group; Z represents a carboxyl group, a lower alkoxycarbonyl group, a tetrazolyl group, a hydroxyl group or -CONR₃R₄ wherein R₃ and R₄ each represents a hydrogen atom or a lower alkyl group; n represents an integer of from 1 to 6; and the bond between the 2- and 3-positions represents a single bond or a double bond; provided that a combination wherein Y₁, Y₂, and R₂ each represents a hydrogen atom, R₁ represents a phenyl group, n represents 1, Z represents a carboxyl group or an alkoxycar­ bonyl group, and the bond represents a double bond, and a combination wherein Y₁, Y₂, and R₁ each represents a hydrogen atom, R₂ represents a phenyl group, n represents 1, Z represents a carboxyl group or an alkoxycarbonyl group, and the bond represents a double bond are excluded, and pharmaceutically acceptable salts thereof are disclosed. These compounds have uricosuric activity, diuretic activity and antihypertensive activity, and are useful as pharmaceu­ ticals.

Description: This invention relates to benzopyran derivatives and salts thereof which have uricosuric activity, diuretic activity, and antihypertensive activity and are, therefore, useful as pharmaceuticals. Known compounds having diuretic and uricosuric activities include tienilic acid ([2,3-dichloro-4-(2-thenoyl)phenoxy]acetic acid) as disclosed in U.S. Patent 3,758,506, indacrinone ([6,7-dichloro-2,3-dihydro-2-methyl-1-oxo-2-phenyl-1H-inden-5-yl)oxy]acetic acid) as disclosed in Journal of Medicinal Chemistry , Vol. 21, 437-442 (1978), and the compounds disclosed in J.Med.Chem. 27 , 1016-1026, (1984), US-A-4 401 669 and DE-A-33 32 162. However, these compounds are unsatisfactory in uricosuric, diuretic, and antihypertensive activities. Also, a benzopyran derivative is reported in Arzneim.-Forsch ., Vol. 30, 2126 (1980) as having diuretic and saluretic activities, but this compound has no uricosuric activity. DD-A-24 560 discloses flavonyloxy acetamides of the formula: in which R and R¹ each inter alia represent methyl, ethyl, butyl or in which R is isobutyl and R¹ is hydrogen. It is disclosed that the flavonyloxy acetamide possess coronary dilating properties. DE-A-11 93 511 and DE-A-12 10 882 disclose 7-oxychromone derivatives of the formula wherein R is C₁-C₄-alkyl or alkyl and the alkylene moiety has 1 to 4 carbon atoms. These compounds exhibit coronary dilating properties. GB-A-803 372 discloses hydroxy-chromone derivatives of the formula wherein R and R¹ are both CH₃ groups and R² is inter alia hydrogen or ethyl. The compounds are disclosed to exhibit coronary dilating activity. FR-A-2 100 692 discloses compounds of the formula wherein R¹ represents an optionally substituted alkyl group, R² and R³ represent hydrogen, alkoxy, nitro, halogen, sulfo or hydroxy and R⁴ represents hydrogen, alkyl or -COOH. These compounds are used as food additive to promote an increase in body weight. In J.Chem.Soc. 12 , 5121-5125 (1962) compounds of the flavonoid series are disclosed, in particular 3-amino-4′,7-dimethoxyflavone, having bronchodilator activities. ES-A-477,270 discloses isoflavone compounds of the formula: wherein R is hydrogen or hydroxy, R¹ and R³ are hydrogen or methyl and R² is dimethylaminoethyl or diethylaminoethyl. In Chem. Zentralblatt 12 , 3472 (1965) 1,1,1-trichloro-2-hydroxy-3[carboxymethoxybenzofuryl-(3′)]-propane derivatives are disclosed which have antimycotic activity. As a result of extensive investigations it has now been found that the novel compounds represented by formula (I) shown below and salts thereof exhibit excellent uricosuric, diuretic, and antihypertensive activities. The compounds of the present invention are represented by formula I: wherein: R₁ and R₂ each represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted cyclic alkyl group, a mono- or di-lower alkylamino group, a substituted or unsubstituted cyclic amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; Y₁ and Y₂ each represents a hydrogen atom, a lower alkyl group, a halogen atom or a trihalomethyl group; Z represents a carboxyl group, a lower alkoxycaronyl group, a tetrazolyl group, a hydroxyl group or -CONR₃R₄ wherein R₃ and R₄ each represents a hydrogen atom or a lower alkyl group; n represents an integer of from 1 to 6; and the bond between the 2- and 3-positions represents a single bond or a double bond; provided that Y₁ and Y₂ can not simultaneously represent a hydrogen atom. In formula (I), the term "lower alkyl group" as used for R₁, R₂, Y₁, Y₂, R₃, and R₄ means an alkyl group containing from 1 to 6 carbon atoms and includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, t-butyl groups and the like. The term "cyclic alkyl group" as used for R₁ or R₂ includes cyclopropyl, cyclobutyl cyclopentyl, cyclohexyl, cycloheptyl groups and the like, and the cyclic groups may have one or more substituents. Substituents on the cyclic alkyl group include a lower alkyl group and the like. Alkyl groups in the di-lower alkylamino group for R₁ or R₂ may be the same or different. The cyclic amino group of R₁ or R₂ includes 1-pyrrolidinyl, 1-piperidinyl, 1-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl, 1-homopiperazinyl groups and the like, and the cyclic amino group may have one or more substituents. Substituents on the cyclic amino group include a lower alkyl group and the like. The aryl group includes phenyl, naphthyl, biphenyl groups and the like, and the aryl group may have one or more substituents. Substituents on the aryl group include a hydroxyl group, a halogen atom, a lower alkyl group, a lower alkoxy group, and the like. The aralkyl group includes benzyl, phenylethyl, naphthylmethyl, naphthylethyl, biphenylmethyl, phenylpropyl groups and the like, and the aralkyl group may have one or more substituents. Substituents on the aralkyl group include a hydroxyl group, a halogen atom, a lower alkyl group, a lower alkoxy group, and the like. These substituents may be bonded to either the aryl moiety or the alkylene moiety of the aralkyl group. When the aforesaid cyclic alkyl, cylic amino, aryl or aralkyl group has two or more substituents, such substituents may be the same or different. The halogen atom includes fluorine, chlorine, bromine, and iodine atoms. The compound of formula (I) can form alkali metal or alkaline earth metal salts, e.g., a sodium salt, a potassium salt, a calcium salt, a magnesium salt, etc., an ammonium salt, and amine salts, e.g., an N-methylglucamine salt, an ethanolamine salt, etc., in cases where Z represents a carboxyl group or a tetrazolyl group. Also, the compound of formula (I) can form acid addition salts with inorganic acids, e.g., hydrochloric acid, sulfuric acid, etc., or organic acids in cases where R₁ or R₂ represents a mono- or di-lower alkylamino group or a cyclic amino group. Of the compounds of formula (I), a preferred class of compounds is represented by the following formula (I′). wherein X represents a halogen atom, and A represents a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group. A more preferred class of compounds is represented by the above formula (I′) wherein X represents a chlorine atom and A represents a hydrogen atom, a 2-chlorine atom, a 2-methyl group or a 4-methoxy group. The compounds of the present invention can be prepared by one of the following processes a) to e), depending on the definition of the substituents in the compounds of formula (I). In the above formulae, R₁, R₂, Y₁, Y₂, and n are as defined above; R₅ represents a lower alkoxycarbonyl group or a hydroxyl group; and Q represents a halogen atom. The compound of formula (Ia) can be prepared by reacting the compound of formula (II) with the compound of formula (III) in an amount of from 1 to 1.5 moles per mole of the compound of formula (II), in an organic solvent, such as dimethylformamide and acetone, in the presence of a carbonate or hydroxide of an alkali metal or alkaline earth metal, e.g., potassium carbonate, sodium hydroxide, potassium hydroxide, etc. in an amount of from 1 to 2 moles per mole of the compound of formula (II). The reaction can be carried out at from room temperature (e.g., 1 to 30°C) to about 100°C for 0.5 to 24 hours. The solvent is generally used in an amount of from 5 to 100 times (by weight) the amount of the compound of formula (II). In the above formulae, R₁, R₂, Y₁, Y₂, n, and Q are as defined above. The compound of formula (II) can be reacted with the compound of formula (IV) in a known manner as described in Journal of Medicinal Chemistry , Vol. 21, 437-442 (1978) to prepare the compound of formula (V). Then, the compound of formula (V) can be reacted with a metal salt of hydrogen azide, e.g., sodium azide, in the presence of ammonium chloride at from 50 to 100°C for 0.5 to 24 hours in an organic solvent, e.g., dimethylformamide, to prepare the compound of formula (Ib). The metal salt of hydrogen azide and ammonium chloride can be used at a molar ratio of from 1 to 1.5 moles per mole of the compound of formula (V). The solvent is generally used in an amount of from 5 to 100 times (by weight) the amount of the compound of formula (V). In the above formulae, R₁, R₂, Y₁, Y₂, and n are as defined above; and R₆ represents a lower alkyl group. The compound of formula (Ic) can be prepared by reacting the compound of formula (Ia′) with an inorganic base, such as a hydroxide of an alkali metal or alkaline earth metal, in water or a mixed solvent of water and an organic solvent, e.g., ethanol, methanol, dioxane, dimethylformamide, etc. The reaction can be carried out at from room temperature to 50°C for 0.5 to 24 hours. The solvent is generally used in an amount of from 5 to 10 times (by weight) the amount of the compound of formula (Ia′). The inorganic base can be used at a molar ratio of from 1 to 10 moles per mole of the compound of formula (Ia′). The compound of formula (Ic) can also be prepared by reacting the compound of formula (Ia′) with boron tribromide in an organic solvent, e.g., dichloroethane, etc. at from 0 to 100°C for 0.5 to 12 hours. The solvent is generally used in the same amount as that described above. The boron tribromide can be used at a molar ratio of from 1 to 10 moles per mole of the compound of formula (Ia′). In the above formulae, R₁, R₂, Y₁, Y₂, R₃, R₄, n and Q are as defined above. The compound of formula (Ic) can be reacted with a halogenating agent, e.g., thionyl chloride in the absence of solvent or in a solvent, e.g., chloroform, dichloromethane, 1,2-dichloroethane, etc., at from room temperature to 100°C for 30 minutes to 12 hours to prepare the compound of formula (Id). The solvent is generally used in an amount of from 5 to 100 times (by weight) the amount of the compound of formula (Ic). The halogenating agent can be used in an equimolar amount or a molar excess amount to the compound of formula (Ic). The compound of formula (Id) thus obtained can be reacted with the amine NHR₃R₄ in an organic solvent, e.g., benzene, etc., from room temperature to 50°C for 1 to 12 hours to prepare the compound of formula (Ie). The solvent is generally used in an amount of from 5 to 100 times (by weight) the amount of the compound of formula (Id). The amine NHR₃R₄ can be used at a molar ratio of from 1 to 10 moles per mole of the compound of formula (Id). In the above formulae, R₁, R₂, Y₁, Y₂, Z, and n are as defined above. The compound of formula (Ig) can be prepared by catalytic reduction of the compound of formula (If) in an appropriate organic solvent, e.g., methanol, ethanol, etc., in the presence of a catalyst, e.g., platinum (IV) oxide, palladium charcoal etc., in accordance with a known process, as described in Jikken Kagaku Koza , Vol. 21 (Second Volume), 175. The catalytic reduction can be carried out at from room temperature to 50°C until the absorption of of hydrogen atom is completed. The solvent is generally used in an amount of 5 to 200 times (by weight) the amount of the compound of formula (Ie). The catalyst can be used in an amount of from 0.01 to 0.1 part by weight per part by weight of the compound of formula (Ie). The compound of formula (II) which is used as a starting compound in the above-described reactions can be prepared by the following processes f) and g), according to the definition of substituents in the compounds of formula (II). In the above formulae, R₁, Y₁, and Y₂ are as defined above; and R₂₁ represents a lower alkyl group, a substituted or unsubstituted cyclic alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group. The compound of formula (VI) can be reacted with the compound of formula (VII) in an organic solvent, e.g., 1,2-dichloroethane, in the presence of anhydrous aluminum chloride to prepare the compound of formula (VIII). The compound of formula (VIII) can be then reacted with the compound of formula (IX) in the presence of pyridine and piperidine in accordance with a known process, as described in Chemical Abstracts , Vol. 46, 500d, to prepare the compound of formula (X). The compound of formula (X) wherein R₁ is a hydrogen atom, i.e., the compound of formula (Xa) can also be prepared by reacting the compound of formula (VIII) with ethyl formate in the presence of sodium hydride or sodium in accordance with a known process, as described in Chemical Abstracts , Vol. 49, 13981a or Journal of Society India Research , Vol. 113, 347-348 (1952). In this reaction, by-product of formula (VIII′) sometimes produces. The by-product of formula (VIII′) can be converted into the compound of formula (Xa) by heating at from about 140 to about 170°C. The thus obtained compound of formula (X) can then be reacted with anhydrous aluminum chloride in a non-polar organic solvent, e.g., benzene, at from about 50 to about 100°C to prepare the compound of formula (IIa). In the above formulae, R₁, Y₁, and Y₂ are as defined above; and R₂₂ represents a mono- or di-lower alkylamino group or a substituted or unsubstituted cyclic amino group. The compound of formula (VI) can be reacted with acetyl chloride in the presence of anhydrous aluminum chloride to prepare the compound of formula (XI), which can be then reacted with the compound of formula (XII) in accordance with a known process, as described in Synthesis , Vol. 11, 901-903 (1979) to prepare the compound of formula (XIII). The prepared compound (XIII) can be reacted with bromine to obtain the compound of formula (XIV), which can be then reacted with the compound of formula (XV) to prepare the compound of formula (XVI). The compound of formula (XVI) can be reacted with hydrobromic acid to prepare the compound of formula (IIb). The compound of formula (VII) used as a starting compound in process f) can be prepared by reacting a compound of formula (XVII) with thionyl chloride as shown below. wherein R₂₁ is as defined above. The compound of formula (I) and a salt thereof of the present invention are excellent in uricosuric activity, diuretic activity, and antihypertensive activity and are, therefore, useful as pharmaceuticals. The pharmacological activities of the compound of the present invention are described in the following experiments. In these experiments, the test compounds used are as follows. (a): [(5-Chloro-4-oxo-3-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid (b): [(5-Methyl-4-oxo-3-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid (c): {[5-Chloro-3-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetic acid (d): {[5-Chloro-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetic acid (e): [(3-Benzyl-5-chloro-4-oxo-4H-1-benzopyran-7-yl)oxy]acetic acid 1) Diuretic Activity and Natriuretic Activity: Male rats weighing 150 to 250 g were fasted overnight and, the next morning, orally administered with either (1) 25 mℓ/Kg of physiological saline (control group) or (2) atest compound which was suspended in 0.5 wt% carboxymethylcellulose. Urine after dosing was collected for 5 hours, and urinary volume and sodium concentration were measured. Each parameter was calculated by subtracting the value of the control group from that of the test group. The results obtained are shown in Table 1 below. As is apparent from the Table 1, the compounds of the present invention exhibited higher diuretic and natriuretic activities as compared with tienilic acid. 2) Uricosuric Activity: Male rats weighing 150 to 250 g were fasted overnight and, the next morning, orally administered with either (1) 25 mℓ/Kg of physiological saline (control group) or (2) a test compound which was suspended in 0.5 wt% carboxymethylcellulose. After 60 minutes from the administration of the test compound, urine over a period of 30 minutes was collected. Thereafter, blood was taken from the arotid artery under anesthesia, and uric acid concentrations in the urine and the serum were determined by the enzyme method. On the other hand, creatine concentrations in the urine and the serum were determined by a Jaffe's method to obtain the fractional excretion of uric acid. Percent of uric acid excretion was calculated by dividing the value of fractional excretion in the test group by that in the control group. The results obtained are shown in Table 2 below. As is apparent from the Table 2, the compounds of the present invention exhibited superior uricosuric activity to tienilic acid. 3) Antihypertensive Activity: Four-week-old male rats weighing 120 to 150 g were subcutaneously injected with DOCA (desoxycorticosterone acetate) and fed on a 1 % saline solution to cause hypertension in accordance with the method of Seyle, et al. as described in American Heart Journal , Vol. 37, 1009 (1949). The test compound was orally administered to the hypertensive rats once a day for 4 weeks. The blood pressure of the animal was measured by a tail cuff method every one week from the start of the administration. The results obtained are shown in Table 3 below. In Table 3, antihypertensive activity (ΔmmHg) was obtained by subtracting the systolic pressure of the test group from that of the control group. As is apparent from the Table 3, the compounds of the present invention exhibited higher antihypertensive activity than tienilic acid. As is apparent from the above results, the compound of the present invention exhibited excellent uricosuric, diuretic and antihypertensive activities as compared with the representative known compound. The compound of the present invention has a low toxicity, and the acute toxicity (LD₅₀) of typical compounds of formula (I) is shown in the following Table 4. The compound of the present invention can be administered orally or parenterally. The oral dosage level of the compound of the present invention is usually in the range of from 10 to 200 mg per adult human (about 50 Kg body weight) per day. The pharmaceutical preparations containing the compound of the present invention include tablets, capsules, powder, granules and the like. The preparations can be produced by conventional techniques using appropriate additives such as lactose, corn starch, crystalline cellulose, polyvinyl alcohol, carboxymethyl cellulose calcium, magnesium stearate, talc and the like. The present invention is now illustrated in greater detail by the following Reference Examples and Examples but it should be understood that the present invention is not limited thereto. REFERENCE EXAMPLE 1 1) Synthesis of 1-(2-chloro-6-hydroxy-4-methoxy)phenyl-2-(2-methylphenyl)-1-ethanone In 4 ℓ of 1,2-dichloroethane were suspended 390 g of anhydrous aluminum chloride and 38 g of zinc chloride, and the suspension was stirred for 30 minutes at 0°C. To the resulting solution was added 400 mℓ of a 1,2-dichloroethane solution containing 483 g of 5-chloro-1,3-dimethoxybenzene. To the mixture was added dropwise 400 mℓ of a 1,2-dichloroethane solution containing 470 g of 2-methylphenylacetyl chloride over a period of 1.5 hours while maintaining the temperature at -10°C by cooling with ice and sodium chloride. After the addition, the reaction mixture was stirred at room temperature for 1 hour and then at 70°C for an additional one hour. The reaction mixture was poured into ice-water containing hydrochloric acid and extracted with chloroform. The chloroform layer was washed with water, dried over sodium sulfate, and distilled under reduced pressure to remove the solvent. The residue was recrystallized from benzene to obtain 380 g of the entitled compound having a melting point of 107 to 108°C. 2) Synthesis of 5-chloro-7-methoxy-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran In one liter of 1,4-dioxane was dissolved 303 g of the above obtained compound, and 1.3 ℓ of ethyl formate was added thereto. To the mixture was added 113 g of 60% sodium hydride in small portions under ice-cooling while stirring. The mixture was heated at 40°C for 3 hours. The reaction mixture was poured into ice-water containing hydrochloric acid and extracted with chloroform. The chloroform layer was washed with water, dried over sodium sulfate, and distilled under reduced pressure to remove the solvent. The residue was heated at 160°C under reduced pressure for 1 hour, followed by recrystallization from benzene to obtain 250 g of the entitled compound having a melting point of 159 to 160°C. 3) Synthesis of 5-chloro-7-hydroxy-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran In 2.5 mℓ of benzene was suspended 225 g of the above obtained compound, and 300 g of anhydrous aluminum chloride was added thereto, followed by refluxing for 1 hour. After cooling, 1.5 ℓ of petroleum ether was added to the reaction mixture, followed by allowing to stand overnight. The organic layer was removed by decantation. Ice-water was added to the residue, and the mixture was vigorously agitated. The insoluble crystals were collected by filtration, washed with hot water, and dried to obtain 210 g of the entitled compound having a melting point of above 290°C. REFERENCE EXAMPLES 2 TO 12 In the same manner as in Reference Example 1, the following compounds were prepared. REFERENCE EXAMPLE 13 1) Synthesis of 1-(2-chloro-6-hydroxy-4-methoxy)phenyl-3-methyl-1-butanone The entitled compound was prepared in the same manner as in Reference Example 1-1). 2) Synthesis of 5-chloro-3-isopropyl-7-methoxy-4-oxo-4H-1-benzopyran In 230 mℓ of ethyl formate was dissolved 44 g of the above obtained compound, and 12.4 g of sodium wire was added to the solution, followed by stirring at room temperature for 3 hours. After sodium was completely dissolved, the reaction mixture was heated up to 60°C and stirred at that temperature for 2 hours. The reaction mixture was poured into ice-water containing hydrochloric acid, and the organic layer was separated. The aqueous layer was extracted with chloroform. The organic layer and the chloroform layer were combined, washed successively with water and a saturated sodium chloride aqueous solution, and dried over sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was heated at 160°C for 1 hour under reduced pressure. Recrystallization of the residue from benzene gave 17.6 g of the entitled compound having a melting point of 177 to 179°C. 3) Synthesis of 5-chloro-3-isopropyl-7-hydroxy-4-oxo-4H-1-benzopyran The entitled compound was prepared in the same manner as in Reference Example 1-3) from the compound obtained in 2) above. Melting Point: 256-260°C (with decomposition). REFERENCE EXAMPLE 14 5-Chloro-3-cyclopentyl-7-hydroxy-4-oxo-4H-1-benzopyran was prepared in the same manner as in Reference Example 13. Melting Point: 282-284°C. REFERENCE EXAMPLE 15 1) Synthesis of 1-(2,3-dichloro-6-hydroxy-4-methoxy)-phenyl-2-phenyl-1-ethanone The entitled compound was prepared in the same manner as in Reference Example 1-1). Melting Point: 179-180°C. 2) Synthesis of 5,6-dichloro-7-methoxy-4-oxo-3-phenyl-4H-1-benzopyran A mixture comprising 28.4 g of the above compound obtained in 1) above, 173 mℓ of ethyl orthoformate, 230 mℓ of dried pyridine, and 9 mℓ of dried piperidine was refluxed for 4 hours. The reaction mixture was poured into ice-water containing hydrochloric acid, and the insoluble material was extracted with dichloromethane. The organic layer was washed with water and dried over sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was subjected to silica gel column chromatography. The resulting crude crystals were recrystallized from benzene to obtain 14.3 g of the entitled compound having a melting point of 216-218°C. 3) Synthesis of 5,6-dichloro-7-hydroxy-4-oxo-3-phenyl-4H-1-benzopyran The entitled compound was prepared from the compound obtained in 2) above in the same manner as in Reference Example 1-3). Melting Point: above 290°C. REFERENCE EXAMPLES 16 TO 21 In the same manner as in Reference Example 15, the following compounds were prepared. REFERENCE EXAMPLE 22 1) Syntheis of 5-chloro-7-methoxy-2-methyl-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran In 150 mℓ of dried pyridine was dissolved 17.6 g of 1-(2-chloro-6-hydroxy-4-methoxy)phenyl-2-(2-methylphenyl)-1-ethanone prepared in Reference Example 1-1), and 6.5 mℓ of dried piperidine and 75 g of ethyl orthoacetate were added to the solution, followed by refluxing for 7 hours. After cooling, the reaction mixture was poured into dilute hydrochloric acid and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and distilled under reduced pressure to remove the solvent. The residue was subjected to silica gel column chromatography. Recrystallization of the resulting crude crystals from ethanol gave 3.0 g of the entitled compound having a melting point of 138 to 140°C. 2) Synthesis of 5-chloro-7-hydroxy-2-methyl-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran The entitled compound was prepared from the compound obtained in 1) above in the same manner as in Reference Example 1-3). REFERENCE EXAMPLE 23 In the same manner as in Reference Example 22, 5-chloro-7-hydroxy-2-methyl-3-phenyl-4-oxo-4H-1-benzopyran was prepared. Melting Point: above 300°C. REFERENCE EXAMPLE 24 1) Synthesis of 2-chloro-6-hydroxy-4-methoxyacetophenone To 460 mℓ of 1,2-dichloroethane were added 46.4 g of ground anhydrous aluminum chloride and 4.74 g of zinc chloride, followed by stirring for 30 minutes. Under ice-cooling, a solution of 60 g of 5-chloro-1,3-dimethoxybenzene in 150 mℓ of 1,2-dichloroethane was added thereto. To the reaction mixture was added dropwise 27.3 g of acetyl chloride over a period of 30 minutes while maintaining the temperature at -10 to -15°C. After the addition, the stirring was continued at 0°C for 2 hours and then at 70°C for an additional 1.5 hours. The reaction mixture was allowed to cool, poured into ice-water containing hydrochloric acid, and extracted with chloroform. The chloroform layer was dried over sodium sulfate, and concentrated under reduced pressure. The residue was crystallized from petroleum ether to obtain 45.0 g of the entitled compound containing 4-chloro-2-hydroxy-6-methoxy-acetophenone as a by-product. 2) Synthesis of 1-(2-chloro-6-hydroxy-4-methoxy)phenyl-3-dimethylamino-2-propen-1-one In 44.0 mℓ of dimethylformamide dimethylacetal was dissolved 44.0 g of the above obtained compound, and the solution was stirred at 60°C for 30 minutes. Excess of the dimethylformamide dimethylacetal was removed by distillation under reduced pressure, and the residue was purified by silica gel column chromatography to obtain 26 g of crude crystals of the entitled compound. 3) Synthesis of 3-bromo-5-chloro-7-methoxy-4-oxo-4H-1-benzopyran In 260 mℓ of chloroform was dissolved 26 g of the above obtained compound. A solution of 5.24 mℓ of bromine in 5 mℓ of chloroform was added dropwise to the solution under cooling to -10 to -15°C while stirring. The stirring was continued at 0°C for an additional 30 minutes. Water was added thereto, followed by stirring, and the reaction mixture was extracted with chloroform. The chloroform layer was dried over sodium sulfate and concentrated under reduced pressure. The resulting residue was recrystallized from benzene to obtain 8.4 g of the entitled compound having a melting point of 176-177°C. 4) Synthesis of 5-chloro-7-methoxy-4-oxo-3-piperidinyl-4H-1-benzopyran In 20 mℓ of hexamethylphosphoric triamide was dissolved 2.8 g of the above obtained compound, and 5.7 mℓ of piperidine was added thereto, followed by stirring at room temperature for 2 days. The reaction mixture was poured into ice-water, and the precipitated crystals were collected by filtration. The resulting crude crystals were subjected to silica gel column chromatography to obtain 2.8 g of the entitled compound having a melting point of 122-125°C. 5) Synthesis of 5-chloro-7-hydroxy-4-oxo-3-(1-piperidinyl)-4H-1-benzopyran hydrobromide In 130 mℓ of 48 wt% hydrobromic acid was suspended 2.8 g of the above obtained compound, and the suspension was stirred at 150°C for 6 hours. The reaction mixture was cooled, and the precipitated crystals were collected by filtration, washed with water, and dried to yield 3.3 g of the entitled compound. EXAMPLE 1 Synthesis of ethyl { [5-chloro-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetate In 1 ℓ of acetone was suspended 114 g of 5-chloro-7-hydroxy-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran, and 60.4 g of anhydrous potassium carbonate and 73.0 g of ethyl bromoacetate were added thereto, followed by refluxing for 1.5 hours. After cooling, the insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure. Recrystallization of the residue from ethanol gave 132 g of the entitled compound having a melting point of 122 to 123°C. EXAMPLES 2 TO 24 In the same manner as in Example 1, the following compounds were prepared. EXAMPLE 25 Synthesis of ethyl{[4-oxo-3-phenyl-5-trifluoromethyl-4H-1-benzopyran-7-yl]oxy}acetate In a stainless steel-made reaction tube were placed 9.5 g of a copper powder and 30 mℓ of hexamethylphosphoric triamide, and 6 mℓ of iodotrifluoromethyl was added thereto in a closed system while cooling with dry ice-acetone. The mixture was heated to 125°C and stirred at that temperature for 2.5 hours. After cooling, 3.5 g of ethyl {[5-iodo-4-oxo-3-phenyl-4H-1-benzopyran-7-yl]oxy}acetate was added thereto. Nitrogen gas was introduced in the atmosphere, and the mixture was stirred at 45°C for 12 hours. The reaction mixture was poured into 500 mℓ of a benzene-ethyl acetate mixture (1:1 by volume), and 500 mℓ of ice-water was then added thereto, followed by stirring for 30 minutes. The precipitate thus formed was removed by filtration through Celite (R), an the filtrate was washed with water an dried over sodium sulfate. The solvent was removed by distillation under reduced pressure, and the residue was subjected to silica gel column chromatography. Recrystallization of the resulting crude crystals from ethanol gave 2.65 g of the entitled compound having a melting point of 139 to 140°C. EXAMPLE 26 Synthesis of ethyl{(5-chloro-3-(4-methoxyphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetate In 150 mℓ of acetone was dissolved 5.5 g of ethyl {(5-chloro-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetate under heating, and 4.8 g of anhydrous potassium carbonate was added thereto. To the solution was added 3.4 mℓ of methyl iodide, followed by refluxing for 2 hours. After cooling, the solvent was removed by distillation under reduced pressure. Water was added to the residue, and the insoluble material was extracted with ethyl acetate. The organic layer was dried over sodium sulfate and distilled under reduced pressure to remove the solvent. The residue was recrystallized from ethanol-chloroform to obtain 5.0 g of the entitled compound having a melting point of 121 to 122°C. EXAMPLES 27 AND 28 In the same manner as in Example 26, the following compounds were prepared. EXAMPLE 29 Synthesis of{[5-chloro-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetic acid In 1.2 ℓ of ethanol was suspended 132 g of ethyl {[5-chloro-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetate, and 0.53 ℓ of a 1N sodium hydroxide aqueous solution was slowly added dropwise to the suspension at room temperature, followed by stirring at room temperature for 3 hours. The insoluble material was removed by filtration, and the filtrate was acidified with hydrochloric acid while ice-cooling and stirring. The stirring was continued at room temperature overnight. The precipitated crystals were collected by filtration, washed with water, ant dried to obtain 105 g of the entitled compound having a melting point of 191 to 192°C. NMR δppm (DMSO-d₆, TMS): 2.16 (3H, s), 4.94 (2H, s), 7.1-7.3 (4H, m), 8.20 (1H, s) EXAMPLES 30 TO 53 In the same manner as in Example 29, the following compounds were prepared. EXAMPLE 54 Synthesis of{[5-chloro-3-(2-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetic acid In 100 mℓ of dried dichloromethane was dissolved 1.7 g of ethyl {[5-chloro-3-(2-hydroxyphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetate, and the solution was cooled with dry ice-acetone. Three mililiters of boron tribromide were added to the cooled solution in small portions, and the resulting mixture was refluxed for 3 hours. After cooling, the solvent was removed by distillation under reduced pressure, and to the residue was added dilute hydrochloric acid. The precipitated crystals were collected by filtration, washed with water, air-dried, and recrystallized from ethanol to obtain 1.0 g of the entitled compound having a melting point of 188-189°C (with decomposition). NMR δppm (DMSO-d₆, TMS): 4.87 (2H, s), 6.65-6.90 (2H, m), 7.07 (2H, s), 6.9-5-7.30 (2H, m), 8.10 (1H, s), 9.22 (1H, s) EXAMPLE 55 Synthesis of{[5-chloro-2,3-dihydro-4-oxo-3-phenyl-4H-1-benzopyran-7-yl]oxy}acetic acid One gram of {[5-chloro-4-oxo-3-phenyl-4H-1-benzopyran-7-yl]oxy}acetic acid was dissolved in 200 mℓ of methanol while heating, and 50 mg of platinum (IV) oxide was added to the solution. After an equimole of hydrogen was absorbed, the platinum catalyst was removed by filtration. The methanol in the filtrate was removed by distillation, and the residue was recrystallized from chloroform to obtain 0.4 g of the entitled compound having a melting point of 171 to 173°C. NMR δppm (DMSO-d₆, TMS): 4.11 (1H, dd), 4.6-5.0 (4H, m), 6.58 (1H, d), 6.75 (1H, d), 7.30 (5H br. s) EXAMPLE 56 1) Synthesis of{ [ 5-chloro-3-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-7-yl]oxy}acetonitrile In 50 mℓ of acetone was dissolved 1.4 g of 5-chloro-3-(2-chlorophenyl)-7-hydroxy-4-oxo-4H-1-benzopyran, and 0.7 g of anhydrous potassium carbonate, 0.38 g of chloroacetonitrile and 0.15 g of potassium iodide were added to the solution, followed by refluxing for 8 hours. Water was added to the reaction mixture, and the precipitated crystals were collected by filtration. Recrystallization of the crystals from ethanol gave 1.4 g of the entitled compound having a melting point of 174 to 175°C. 2) Synthesis of{[5-chloro-3-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-7-yl]oxymethyl}tetrazole In 60 mℓ of dimethylformamide was dissolved 1.2 g of {[5-chloro-3-(2-chlorophenyl-4-oxo-4H-1-benzopyran-7-yl]oxy}acetonitrile. To the solution were added 0.26 g of sodium azide and 0.21 g of ammonium chloride, followed by allowing the mixture to react at 100 to 110°C for 12 hours. The reaction mixture was poured into ice-water containing hydrochloric acid, and the precipitated crystals were collected by filtration, washed with water, and dried to obtain 1.1 g of the entitled compound having a melting point of 192 to 195°C. NMR δppm (DMSO-d₆, TMS): 5.64 (2H, s), 7.16-7.56 (6H, m), 8.25 (1H, s)

Claims: Claims for the following Contracting States: BE, CH, DE, FR, GB, IT, LI, NL, SE 1. A benzopyran derivative represented by the formula wherein: R₁ and R₂ each represent a hydrogen atom, a lower alkyl group, a substituted or unsubstituted cyclic alkyl group, a mono- or di-lower alkylamino group, a substituted or unsubstituted cyclic amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; Y₁ and Y₂ each represent a hydrogen atom, a lower alkyl group, a halogen atom or a trihalomethyl group; Z represents a carboxyl group, a lower alkoxycarbonyl group, a tetrazolyl group, a hydroxyl group or -CONR₃R₄ wherein R₃ and R₄ each represents a hydrogen atom or a lower alkyl group; n represents an integer of from 1 to 6; and the bond between the 2- and 3-positions represents a single bond or a double bond; provided that Y₁ and Y₂ can not simultaneously represent a hydrogen atom; and pharmaceutically acceptable salts thereof. 2. A benzopyran derivative and pharmaceutically acceptable salts thereof as claimed in claim 1, wherein R₂ represents a phenyl group which may be substituted with a halogen atom, a lower alkyl group or a lower alkoxy group, R₁ represents a hydrogen atom, Y₁ represents a halogen atom, Y₂ represents a hydrogen atom, n represents 1, and Z represents a carboxyl group. 3. The compounds according to claim 1, namely [(5-Chloro-4-oxo-3-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid [(5-Methyl-4-oxo-3-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid [5-Chloro-3-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-7-yl]oxyacetic acid [5-Chloro-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxyacetic acid [(3-Benzyl-5-chloro-4-oxo-4H-1-benzopyran-7-yl]oxy]acetic acid and the pharmaceutically acceptable salts thereof. 4. The compounds of claims 1 to 3 for use in a method for treatment of the human or animal body. 5. A process for preparing a benzopyran derivative of formula (I) wherein: R₁ and R₂ each represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted cyclic alkyl group, a mono- or di-lower alkylamino group, a substituted or unsubstituted cyclic amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; Y₁ and Y₂ each represents a hydrogen atom, a lower alkyl group, a halogen atom or a trihalomethyl group; Z represents a carboxyl group, a lower alkoxycarbonyl group, a tetrazolyl group, a hydroxyl group or -CONR₃R₄ wherein R₃ and R₄ each represents a hydrogen atom or a lower alkyl group; n represents an integer of from 1 to 6; and the bond between the 2- and 3-positions represents a single bond or a double bond; provided that Y₁ and Y₂ can not simultaneously represent a hydrogen atom; and pharmaceutically acceptable salts thereof, which comprises: 1) reacting a compound of formula (II) wherein R₁, R₂, Y₁, and Y₂ are as defined above; with the compound of formula (III) Q(CH₂) n R₅ wherein n is as defined above, R₅ represents a lower alkoxycarbonyl group or a hydroxyl group, and Q represents a halogen atom; or 2) reacting the compound of formula (V) wherein R₁, R₂, Y₁, Y₂, and n are as defined above, with a metal salt of hydrogen azide; or 3) reacting the compound of formula (Ia′) wherein R₁, R₂, Y₁, Y₂, and n are as defined above, and R₆ represents a lower alkyl group, with an inorganic base or boron tribromide; or 4) reacting the compound of formula (Id) wherein R₁, R₂, Y₁, Y₂, n and Q are as defined above, with an amine NHR₃R₄ wherein R₃ and R₄ are as defined above; or 5) reducing the compound of formula (If) wherein R₁, R₂, Y₁, Y₂, Z and n are as defined above, in the presence of platinum (IV) oxide or palladium charcoal as a catalyst. 6. A pharmaceutical composition comprising at least one of the compounds of claims 1 to 3, optionally together with pharmaceutically acceptable carriers and/or additives. 7. A process for preparing a pharmaceutical composition according to claim 6 which comprises incorporating at least one of the compounds of claims 1 to 3 into a suitable carrier and/or additive. 8. The use of at least one compound of claims 1 to 3 for preparing a pharmaceutical composition having uricosuric, diuretic and antihypertensive activity. Claims for the following Contracting States: AT, ES 1. A process for preparing a benzopyran derivative of formula (I) wherein: R₁ and R₂ each represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted cyclic alkyl group, a mono- or di-lower alkylamino group, a substituted or unsubstituted cyclic amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; Y₁ and Y₂ each represents a hydrogen atom, a lower alkyl group, a halogen atom or a trihalomethyl group; Z represents a carboxyl group, a lower alkoxycarbonyl group, a tetrazolyl group, a hydroxyl group or -CONR₃R₄ wherein R₃ and R₄ each represents a hydrogen atom or a lower alkyl group; n represents an integer of from 1 to 6; and the bond between the 2- and 3-positions represents a single bond or a double bond; provided that Y₁ and Y₂ can not simultaneously represent a hydrogen atom; and pharmaceutically acceptable salts thereof, which comprises: 1) reacting a compound of formula (II) wherein R₁, R₂, Y₁, and Y₂ are as defined above; with the compound of formula (III) Q(CH₂) n R₅ wherein n is as defined above, R₅ represents a lower alkoxycarbonyl group or a hydroxyl group, and Q represents a halogen atom; or 2) reacting the compound of formula (V) wherein R₁, R₂, Y₁, Y₂, and n are as defined above, with a metal salt of hydrogen azide; or 3) reacting the compound of formula (Ia′) wherein R₁, R₂, Y₁, Y₂, and n are as defined above, and R₆ represents a lower alkyl group, with an inorganic base or boron tribromide; or 4) reacting the compound of formula (Id) wherein R₁, R₂, Y₁, Y₂, n and Q are as defined above, with an amine NHR₃R₄ wherein R 3 and R₄ are as defined above; or 5) reducing the compound of formula (If) wherein R₁, R₂, Y₁, Y₂, Z and n are as defined above, in the presence of platinum (IV) oxide or palladium charcoal as a catalyst. 2. The process of claim 1, wherein a benzopyran derivative and pharmaceutically acceptable salts thereof of formula (I) wherein R₂ represents a phenyl group which may be substituted with a halogen atom, a lower alkyl group or a lower alkoxy group, R₁ represents a hydrogen atom, Y₁ represents a halogen atom, Y₂ represents a hydrogen atom, n represents 1, and Z represents a carboxyl group, are obtained. 3. The process of claim 1, wherein the following compounds are obtained: [(5-Chloro-4-oxo-3-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid [(5-Methyl-4-oxo-3-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid [5-Chloro-3-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-7-yl]oxyacetic acid [5-Chloro-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxyacetic acid [(3-Benzyl-5-chloro-4-oxo-4H-1-benzopyran-7-yl)oxy]acetic acid and the pharmaceutical acceptable salts thereof. 4. A process for preparing a pharmaceutically composition comprising at least one of the compounds as defined in claims 1 to 3, optionally together with pharmaceutically acceptable carriers and/or additives which comprises incorporating at least one of the compounds of claims 1 to 3 into a suitable carrier and/or additive. Claims for the following Contracting State: GR 1. A benzopyran derivative represented by the formula wherein: R₁ and R₂ each represent a hydrogen atom, a lower alkyl group, a substituted or unsubstituted cyclic alkyl group, a mono- or di-lower alkylamino group, a substituted or unsubitituted cyclic amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; Y₁ and Y₂ each represent a hydrogen atom, a lower alkyl group, a halogen atom or a trihalomethyl group; Z represents a carboxyl group, a lower alkoxycarbonyl group, a tetrazolyl group, a hydoxyl group or -CONR₃R₄ wherein R₃ and R₄ each represents a hydrogen atom or a lower alkyl group; n represents an integer of from 1 to 6; and the bond between the 2- and 3-positions represents a single bond or a double bond; provided that Y₁ and Y₂ can not simultaneously represent a hydrogen atom; and pharmaceutically acceptable salts thereof. 2. A benzopyran derivative and pharmaceutically acceptable salts thereof as claimed in claim 1, wherein R₂ represents a phenyl group which may be substituted with a halogen atom, a lower alkyl group or a lower alkoxy group, R₁ represents a hydrogen atom, Y₁ represents a halogen atom, Y₂ represents a hydrogen atom, n represents 1, and Z represents a carboxyl group. 3. The compounds according to claim 1, namely [(5-Chloro-4-oxo-3-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid [(5-Methyl-4-oxo-1-phenyl-4H-1-benzopyran-7-yl)oxy]acetic acid [5-Chloro-3-(2-chlorophenyl)-4-oxo-4H-1-benzopyran-7-yl]oxyacetic acid [5-Chloro-3-(2-methylphenyl)-4-oxo-4H-1-benzopyran-7-yl]oxyacetic acid [(3-Benzyl-5-chloro-4-oxo-4H-1-benzopyran-7-yl)oxy]acetic acid and the pharmaceutically acceptable salts thereof. 4. The compounds of claims 1 to 3 for use in a method for treatment of the human or animal body. 5. A process for preparing a benzopyran derivative of formula (I) wherein: R₁ and R₂ each represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted cyclic alkyl group, a mono- or di-lower alkylamino group, a substituted or unsubstituted cyclic amino group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aralkyl group; Y₁ and Y₂ each represents a hydrogen atom, a lower alkyl group, a halogen atom or a trihalomethyl group; Z represents a carboxyl group, a lower alkoxycarbonyl group, a tetrazolyl group, a hydroxyl group or -CONR₃R₄ wherein R₃ and R₄ each represents a hydrogen atom or a lower alkyl group; n represents an integer of from 1 to 6; and the bond between the 2- and 3-positions represents a single bond or a double bond; provided that Y₁ and Y₂ can not simultaneously represent a hydrogen atom; and pharmaceutically acceptable salts thereof, which comprises: 1) reacting a compound of formula (II) wherein R₁, R₂, Y₁, and Y₂ are as defined above; with the compound of formula (III) Q(CH₂) n R₅ wherein n is as defined above, R₅ represents a lower alkoxycarbonyl group or a hydroxyl group, and Q represents a halogen atom; or 2) reacting the compound of formula (V) wherein R₁, R₂, Y₁, Y₂, and n are as defined above, with a metal salt of hydrogen azide; or 3) reacting the compound of formula (Ia′) wherein R₁, R₂, Y₁, Y₂, and n are as defined above, and R₆ represents a lower alkyl group, with an inorganic base or boron tribromide; or 4) reacting the compound of formula (Id) wherein R₁, R₂, Y₁, Y₂, n and Q are as defined above, with an amine NHR₃R₄ wherein R₃ and R₄ are as defined above; or 5) reducing the compound of formula (If) wherein R₁, R₂, Y₁, Y₂, Z and n are as defined above, in the presence of platinum (IV) oxide or palladium charcoal as a catalyst. 6. A process for preparing a pharmaceutical composition comprising at least one of the compounds of claims 1 to 3, optionally together with pharmaceutically acceptable carriers and/or additives which comprises incorporating at least one of the compounds of claims 1 to 3 into a suitable carrier and/or additive.

Inventors: KITAGAWA, MASAYUKI DAIICHI SEIYAKU RESEARCH INST., TANAKA, MAKOTO DAIICHI SEIYAKU RESEARCH INST.
Applicants: DAIICHI SEIYAKU CO., LTD.
Application year: 1987
Main classification: C07D311
IPC codes: A61K31, A61P9, A61P7, C07D405, C07D311, A61P19